HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Saved in:
| Title: | HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. |
|---|---|
| Authors: | Jerusalem G; Department of Medical Oncology, Centre Hospitalier Universitaire du Sart-Tilman, University of Liege, Liège, Belgium. g.jerusalem@chu.ulg.ac.be., Lancellotti P; GIGA Cardiovascular Sciences, Department of Cardiology, Centre Hospitalier Universitaire du Sart-Tilman, University of Liege, Liège, Belgium., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2019 Sep; Vol. 177 (2), pp. 237-250. Date of Electronic Publication: 2019 Jun 05. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
